.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,932,630

« Back to Dashboard

Details for Patent: 8,932,630

Title:Opioid agonist/antagonist combinations
Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Inventor(s): Kaiko; Robert F. (Weston, CT), Colucci; Robert D. (Newton, CT)
Assignee: Purdue Pharma L.P (Norwalk, CT)
Filing Date:Sep 18, 2014
Application Number:14/490,470
Claims:1. An immediate release oral dosage form, comprising: an orally therapeutically effective dose of an opioid agonist selected from buprenorphine and pharmaceutically acceptable salts thereof; and an opioid antagonist selected from naltrexone, naloxone, nalmephene, cyclazocine, levallorphan, and mixtures thereof, and pharmaceutically acceptable salts thereof; said dosage form having a ratio of opioid antagonist to opioid agonist that provides a combination product which is therapeutically effective when the combination is administered orally, but which (i) is aversive in physically dependent human subjects when orally abused at a higher dose than said therapeutically effective dose; and (ii) maintains a therapeutic effect but does not increase therapeutic efficacy of said opioid agonist relative to the same therapeutic dose of opioid agonist when administered to human patients without said opioid antagonist.

2. The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from the group consisting of an NSAID, a COX-2 inhibitor, acetaminophen, aspirin, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, an antitussive, an expectorant, a decongestant, and an antihistamine and mixtures thereof.

3. The oral dosage form of claim 1, further comprising one or more pharmaceutically acceptable inert excipients.

4. The oral dosage form of claim 1, wherein said opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof.

5. The oral dosage form of claim 4, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof.

6. The oral dosage form of claim 4, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2 mg to about 64 mg hydromorphone hydrochloride.

7. The oral dosage form of claim 4, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof.

8. The oral dosage form of claim 4, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg oxycodone or a pharmaceutically acceptable salt thereof.

9. The oral dosage form of claim 4, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof.

10. The oral dosage form of claim 4, wherein the combination is aversive in physically dependent human subjects when orally abused at about 2-3 times said therapeutically effective dose.

11. The oral dosage form of claim 4, wherein the dosage form comprises hydroxypropylmethylcellulose.

12. The oral dosage form of claim 4, wherein the dosage form comprises polyethylene glycol.

13. The oral dosage form of claim 4, wherein the dosage form includes a carbohydrate.

14. The oral dosage form of claim 4, wherein the dosage form is in the form of an oral suppository.

15. A method of reducing oral abuse of an oral opioid formulation comprising administering the oral dosage form of claim 1 to a subject in need thereof.

16. The method of claim 15, wherein said opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg morphine or a pharmaceutically acceptable salt thereof.

18. The method of claim 16, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2.5 mg to about 800 mg oxycodone or a pharmaceutically acceptable salt thereof.

19. The method of claim 16, wherein the dosage form comprises hydroxypropylmethylcellulose.

20. The method of claim 16, wherein the dosage form comprises polyethylene glycol.

21. The method of claim 16, wherein the dosage form is in the form of an oral suppository.

22. The method of claim 16, wherein the dosage form is in the form of a buccal tablet.

23. The method of claim 16, wherein the dosage form further comprises an additional non-opioid drug selected from the group consisting of an NSAID, a COX-2 inhibitor, acetaminophen, aspirin, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, an antitussive, an expectorant, a decongestant, and an antihistamine and mixtures thereof.

24. The method of claim 16, wherein the dosage form further comprises one or more pharmaceutically acceptable inert excipients.

25. The method of claim 16, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof.

26. The method of claim 16, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 2 mg to about 64 mg hydromorphone hydrochloride.

27. The method of claim 16, wherein the buprenorphine or pharmaceutically acceptable salt thereof is present in the dosage form in an amount that is equianalgesic to about 25 mg to about 800 mg tramadol or a pharmaceutically acceptable salt thereof.

28. The method of claim 16, wherein the combination is aversive in physically dependent human subjects when orally abused at about 2-3 times said therapeutically effective dose.

29. The method of claim 16, wherein the dosage form includes a carbohydrate.

30. The oral dosage form of claim 4, wherein the dosage form is in the form of a buccal tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc